Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 (cadonilimab) plus chiauranib in extensive-stage small cell lung cancer after failure of first-line chemo-immunotherapy
CTR20221620Phase 2Terminated
- Sponsor
- Akeso, Inc.
- Start
- Jul 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in small cell lung cancer (SCLC), sponsored by Akeso, Inc.. Started Jul 2022; status: terminated.
02
Drugs
cadonilimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20221620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221620.